Showing results (781-790 of 5,687) with videos related to

Sort By:
Pageof 569
The Oncologist|October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
The Oncologist|October 27, 2025
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysisDouglas Dias E Silva, Laura Sambugaro Pernomian, Matheus Fernandes, et al.
The Oncologist|October 16, 2025
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 resultsIben Spanggaard, Marc Matrana, Caio Rocha Lima, et al.
The Oncologist|August 4, 2025
Dabrafenib and Trametinib vs. Anti-PD(L)1 for the Adjuvant Treatment of Locally Advanced BRAF-Mutant Melanoma: A Systematic Review and Meta-AnalysisDaniel V Araujo, Bruno Lins Souza, Mariana F Seibel, et al.
The Oncologist|July 31, 2025
Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trialSheng Zhang, Mengyang Ju, Qin Wang, et al.
The Oncologist|July 24, 2025
Clinicopathological Evaluation of Triple Negative Breast Cancer Treated with keynote-522 regimenThaer Khoury, Shipra Gandhi, Gary Tozbikian, et al.
The Oncologist|July 28, 2025
Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinibFederico Villanacci, Diego Prost, Francesco Pieri, et al.
The Oncologist|July 28, 2025
An Interdisciplinary Challenge: Responsibilities in German Cancer-related Fatigue Management from the Professional and Patient PerspectiveAnna S Wagner, Marlena Milzer, Karen Steindorf, et al.
The Oncologist|March 28, 2025
Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospitalAntonio Rueda-Lara, David Viñal, Daniel Martínez-Pérez, et al.
The Oncologist|March 28, 2025
Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center studyYvonne Bach, Divya Sharma, Hiroko Aoyama, et al.
Pageof 569